Vnitr Lek 2021, 67(7):404-410 | DOI: 10.36290/vnl.2021.108

Expert consensus on the practical aspects of the cooperation of cardiologist and diabetologist in the management of the patients with chronic heart failure and reduced ejection fraction

Martin Haluzík1, Markéta Kubíčková2, Jiří Veselý2, 3, Aleš Linhart4, Martin Prázný5, Jan Škrha5, Miloš Táborský6, Filip Málek7, 8
1 Centrum diabetologie IKEM, Praha
2 III. interní gerontometabolická klinika, Fakultní nemocnice Hradec Králové a Univerzita Karlova - Lékařská fakulta v Hradci Králové
3 EDUMED, s. r. o., Náchod
4 II. interní klinika Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy v Praze
5 III. interní klinika Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy v Praze
6 I. interní kardiologická klinika Fakultní nemocnice Olomouc a Lékařské fakulty Univerzity Palackého, Olomouc
7 Kardiologické oddělení Nemocnice na Homolce, Praha
8 Interní klinika Fakultní nemocnice Královské Vinohrady a 3. lékařské fakulty Univerzity Karlovy v Praze

Diabetes mellitus is an important risk factor for the development of heart failure and presence of diabetes significantly worsens heart failure outcome. Introduction of gliflozins to the therapy of heart failure is one of the most important novelty. Gliflozins reduce glucose level by the sodium-glucose contransporter 2 inhibition in proximal tubulus in the kidney. Gliflozins are used as effective antidiabetic drugs with improvement of glycemic control without risk of hypoglycemia, gliflozins decrease blood pressure and patients weight. Recent studies have shown that gliflozins significantly reduce risk of cardiovascular complications and heart failure hospitalizations in diabetic patients. Clinical trials with dapagliflozin and empagliflozin have shown reduction of the risk of cardiovascular death and heart failure hospitalization in the patients with heart failure and reduced ejection fraction both in the patients with diabetes and in the patients without diabetes. The aim of the expert consenzus is to summarize practical aspects in the cooperation of cardiologist and diabetologist in the management of the patients with heart failure and reduced ejection fraction in the context of the current guidelines and other treatment options.

Keywords: heart failure with reduce ejection fraction, gliflozins, cardiovascular complications, type 2 diabetes mellitus.

Published: November 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Haluzík M, Kubíčková M, Veselý J, Linhart A, Prázný M, Škrha J, et al.. Expert consensus on the practical aspects of the cooperation of cardiologist and diabetologist in the management of the patients with chronic heart failure and reduced ejection fraction. Vnitr Lek. 2021;67(7):404-410. doi: 10.36290/vnl.2021.108.
Download citation

References

  1. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021.
  2. Lam CSP, Butler J. Victims of Success in Failure. Circulation 2020; 142(12): 1129-1131. Go to original source... Go to PubMed...
  3. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117-2128. Go to original source... Go to PubMed...
  4. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380(4): 347-357. Go to original source... Go to PubMed...
  5. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377(7): 644-657. Go to original source... Go to PubMed...
  6. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381(21): 1995-2008. Go to original source... Go to PubMed...
  7. Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383(15): 1413-1424. Go to original source... Go to PubMed...
  8. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129-2200. Go to original source... Go to PubMed...
  9. PM, Ponikowski P, Anker SD et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21(10): 1169-1186. Go to original source... Go to PubMed...
  10. Writing C, Maddox TM, Januzzi JL, Jr. et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021; 77(6): 772-810. Go to original source... Go to PubMed...
  11. B, Coats AJS, Tsutsui H et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021; 23(3): 352-380. Go to original source... Go to PubMed...
  12. F. Patofyziologie a diagnostika srdečního selhání. In: Táborský M KJ, Linhart A et al. Kardiologie, IV. Srdeční selhání. Česká kardiologická společnost, z.s. 2021: 634.
  13. UK NICE guideline 106: Chronic heart failure in adults: diagnosis and management (12/12/2018), https://www.nice.org.uk/guidance/ng106.
  14. Doporučený postup péče o diabetes mellitus 2. typu Za ČDS: J. Škrha TP, M. Prázný, M. Kvapil Revize ze dne: 31. 5. 2020 https://www.diab.cz/dokumenty/Standardy_DM.pdf.
  15. American Diabetes A. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44(Suppl 1): S111-S124. Go to original source... Go to PubMed...
  16. Honigberg MC VO, Vaduganathan M. Practical Considerations for the Use of Sodium‑Glucose Co‑Transporter 2 Inhibitors in Heart Failure. Circ Heart Fail 2020 Feb; 13(2):e006623. doi: 10.1161/CIRCHEARTFAILURE.119.006623. Epub 2020 Feb 14. PMID: 32059632; PMCID: PMC7543063. Go to original source... Go to PubMed...
  17. Špinar J, Málek F, Špinarová L, Vítovec J, Táborský M, Linhart A. Úprava guidelines ACC pro léčbu srdečního selhání v roce 2021 Cor et Vasa 2021; 63(2): 264-270 | DOI: 10.33678/cor.2021.033. Go to original source...
  18. Málek F, Melenovský V, Krejčí J et al. Stanovisko výboru České asociace srdečního selhání ČKS k organizaci ambulancí srdečního selhání. Cor Vasa 2020; 62: 309-313. Go to original source...
  19. Engelhardt K, Ferguson M, Rosselli JL. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium‑Glucose Cotransporter 2 Inhibitors. Ann Pharmacother 2021; 55(4): 543-548. Go to original source... Go to PubMed...
  20. Táborský M, Skála T, Lazárová M et al. Trends in the treatment and survival of heart failure patients: a nationwide population‑based study in the Czech Republic. ESC Heart Failure 2021, DOI:10.1002/ehf2.13559. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.